**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION****Washington****, D.C. 20549**

**FORM 10-Q**

**[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934****For the quarterly period ended September 30, 2008**

| 000-49707              |
|------------------------|
|                        |
| Commission file number |

| **WIFIMED HOLDINGS COMPANY, INC.**                     |
|--------------------------------------------------------|
|                                                        |
| (Exact name of registrant as specified in its charter) |

| **Nevada**               |   | **58-2412118**                       |
|--------------------------|--------|--------------------------------------|
|                          |   |                                      |
| (State of incorporation) |   | (IRS Employer Identification Number) |

| **2000 RiverEdge Pkwy****Ste. GL 100A            Marietta, Georgia****30062** |
|-------------------------------------------------------------------------------|
|                                                                               |
| (Address of principal executive office)                                       |

| **770-919-7220**                                                |
|-----------------------------------------------------------------|
|                                                                 |
| (Registrant's telephone number,            including area code) |
|                                                            |

Check whether the issuer (1) filed all reports required to filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    X       No                   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.  (Check one):

| Large accelerated filer                       | [   ] |   | Accelerated filer         | [   ] |
|-----------------------------------------------|-----------------|--------|---------------------------|-----------------|
| Non-accelerated filer                         | [   ] |   | Smaller reporting company | [X]             |
| (Do not check if a smaller reporting company) |            |   |                      |            |

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).                    Yes:               No:      X         

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:  There were a total of 43,137,035 shares of the registrant's common stock, par value $.0001 per share, outstanding as of November 13, 2008 and no other classes of common stock.

----

**WifiMed Holdings Company, Inc.****Quarterly Report on Form 10-Q**
| Period Ended September 30, 2008          Table of Contents

PART I .  FINANCIAL INFORMATION          Item 1.  Financial Statements:          Condensed Balance Sheets as of September 30, 2008 (Unaudited) and          December 31, 2007 (Audited)...........................................................................................          Condensed Statement of Operations for the three and nine months              ended September 30, 2008 and September 30, 2007 (Unaudited)........................................          Condensed Statements of Cash Flow for the nine months ended             September 30, 2008 and September 30, 2007 (Unaudited)...................................................          Notes to Financial Statements (Unaudited)...............................................................................          Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations          Item 3.  Quantitative and Qualitative Disclosures About Market Risk...........................................          Item 4T.  Controls and Procedures.............................................................................................          PART II .  OTHER INFORMATION          Item 1.  Legal Proceedings..........................................................................................................          Item 1A Risk Factors.................................................................................................................          Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds..........................................          Item 3.  Defaults Upon Senior Securities.....................................................................................          Item 4.  Submission of Matters to a Vote of Security Holders .....................................................          Item 5.  Other Information..........................................................................................................          Item 6.  Exhibits .........................................................................................................................          SIGNATURES..........................................................................................................................          EXHIBIT INDEX...................................................................................................................... |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**PART I—FINANCIAL INFORMATION**

**Item 1.  Financial Statements**
| WiFiMed Holdings Co., Inc.                               |
|----------------------------------------------------------|
| Consolidated Balance Sheet                               |
| Assets                                                   | **Sept. 30, 2008****(unaudited)** |  | **December 31,            2007** |
|                                                     |  |  |  |
| Current Assets                                           |  |  |  |
| Cash & cash equivalents                              | $6,710 |  | $1,111,218 |
| Accounts receivable, net                                 | 220,036 |  | 269,450 |
| Receivables-employees                                    | 6,206 |  | 0 |
| Prepaid expenses                                         | 27,630 |  | 10,287 |
|                                                     |  |  |  |
|   Total current assets                              | 260,582 |  | 1,390,955 |
|                                                     |  |  |  |
|                                                     |  |  |  |
| Property & equipment (net)                           | 85,336 |  | 88,062 |
| Goodwill                                                 | 5,935,430 |  | 5,035,430 |
| Amortizable intangible assets, net                       | 945,000 |  | 997,500 |
| Advances to affiliated entities and other                | 207,577 |  | 111,775 |
|                                                     |  |  |  |
| Total assets                                             | $7,433,925 |  | $7,623,722 |
|                                                     |  |  |  |
|                                                     |  |  |  |
| Liabilities & Stockholders' Equity                   |  |  |  |
|                                                     |  |  |  |
|                                                     |  |  |  |
| Current Liabilities:                                     |  |  |  |
| Accounts payable                                         | $852,408 |  | $629,174 |
| Accrued expenses                                         | 606,444 |  | 317,447 |
| Unearned revenue & customer deposits                 | 941,682 |  | 764,044 |
| Notes due in less than one year                          | 311,847 |  | 480,105 |
| Current portion of capital lease obligation              | 8,500 |  | 7,599 |
| Convertible notes payable, net of discount               | 691,875 |  | 0 |
|                                                     |  |  |  |
|   Total current liabilities                         | 3,412,756 |  | 2,198,369 |
|                                                     |  |  |  |
|                                                     |  |  |  |
| Long-Term Debt:                                          |  |  |  |
| Convertible, net of discount                             | 1,049,900 |  | 74,900 |
| Capitalized leases                                       | 6,996 |  | 10,889 |
|                                                     |  |  |  |
| Fair value of derivative instruments                     | 1,259,117 |  | 20,674,693 |
|                                                     |  |  |  |
| Stockholders' Equity                                     |  |  |  |
| Common stock-100,000,000 authorized $0.0001 par value    |  |  |  |
| 43,137,035 issued & outstanding (36,279,277 in 2007) | 4,315 |  | 3,629 |
| Additional paid in capital                               | 23,192,082 |  | 17,064,666 |
| Subscriptions receivable                                 | (1,000,000) |  | (1,000,000) |
| Accumulated Deficit                                      | (20,491,241) |  | (31,403,424) |
|                                                     |  |  |  |
| Total Stockholders' Equity                               | 1,705,156 |  | (15,335,129) |
|                                                     |  |  |  |
| Total Liabilities and Stockholders' Equity               | $7,433,925 |  | $7,623,722 |
|                                                     |  |  |  |
|                                                          |  |  |  |

See notes to unaudited interim financial statements.

----

| WiFiMed Holdings Co., Inc.                           |
|------------------------------------------------------|
| Consolidated Statement of Operations                 |
| (unaudited)                                          |
|                                                 |   |
|                                                 |   | Three Months            Ended Sept 30, |  | Nine Months            Ended Sept 30, |
|                                                 |   | **2008** |   | **2007** |  | **2008** |   | **2007** |
|                                                 |   |  |  |  |  |  |  |  |
|                                                 |   |  |  |  |  |  |  |  |
|                                                 |   |  |  |  |  |  |  |  |
| *Revenue:*                                           |   |  |  |  |  |  |  |  |
| Sales of hardware                                    |   | $151,919 |  | $0 |  | $457,649 |  | $0 |
| Software license fees and ongoing support            |   | 259,177 |  | 0 |  | 868,970 |  | 0 |
|                                                 |   |  |  |  |  |  |  |  |
| Total revenue                                        |   | $411,096 |  | $0 |  | $1,326,618 |  | $0 |
|                                                 |   |  |  |  |  |  |  |  |
|                                                 |   |  |  |  |  |  |  |  |
| *Cost and Expenses:*                                 |   |  |  |  |  |  |  |  |
| Cost of tangible goods sold                          |   | 136,444 |  | 3,850 |  | 278,371 |  | 6,766 |
| Research and development                             |   | 15,507 |  | 38,850 |  | 56,621 |  | 179,559 |
| Selling, General & Administrative Expenses       |   | 1,585,846 |  | 564,687 |  | 8,358,288 |  | 1,802,690 |
| Derivative valuation gain                            |   | (3,339,177) |  | 0 |  | (20,331,826) |  | 0 |
| Interest expense, net                                |   | 705,626 |  | 4,715 |  | 2,049,149 |  | 21,336 |
|                                                 |   |  |  |  |  |  |  |  |
| Total costs and expenses                             |   | (895,754) |  | 612,102 |  | (9,589,397) |  | 2,010,351 |
|                                                 |   |  |  |  |  |  |  |  |
|                                                 |   |  |  |  |  |  |  |  |
| Income/(loss) from operations                        |   | 1,306,850 |  | (612,102) |  | 10,916,016 |  | (2,010,351) |
|                                                 |   |  |  |  |  |  |  |  |
| Income Taxes                                         |   | (34) |  | 0 |  | 3,822 |  | 0 |
|                                                 |   |  |  |  |  |  |  |  |
|                                                 |   |  |  |  |  |  |  |  |
|   Net Income (Loss)                             |   | $1,306,884 |  | ($612,102) |  | $10,912,194 |  | ($2,010,351) |
|                                                 |   |  |  |  |  |  |  |  |
| Basic Net Income (Loss) Per Common Share             |   | $0.03 |  | ($0.02) |  | $0.27 |  | ($0.09) |
| Diluted Net Income (Loss) Per Common Share           |   | $0.04 |  |  |  | $0.22 |  |  |
| Weighted Average Common Shares Outstanding (Basic)   |   | 42,405,429 |  | 24,941,383 |  | 40,609,044 |  | 22,836,886 |
| Weighted Average Common Shares Outstanding (Diluted) |   | 62,538,045 |  |  |  | 58,942,369 |  |  |
|                                                      |   |  |  |  |  |  |  |  |

----

| WiFiMed Holdings Co., Inc.                                     |
|----------------------------------------------------------------|
| Consolidated Statement of Cash Flows                           |
| (unaudited)                                                    |
|                                                           | Nine Months Ended Sept 30, |
|                                                           | **2008** |  | **2007** |
|                                                           |  |   |  |
|                                                           |   |   |   |
|                                                           |  |  |  |
| *Cash Flows from Operating Activities:*                        |  |  |  |
| Net Income                                                     | $10,912,194 |  | ($2,010,351) |
| Adjustments required to reconcile net loss to cash flows       |  |  |  |
| from operating activities:                                     |  |  |  |
|    Depreciation, Amortization                        | 92,363 |  | 14,955 |
|    Amortization of debt discount                     | 1,396,875 |  | 0 |
|    Non-cash financing charges                        | 551,250 |  | 0 |
|    Valuation of Derivatives                          | (20,331,826) |  | 0 |
|    Amortization of share based deferred compensation | 2,781,034 |  | 211,530 |
|    Stock issued for services                         | 737,500 |  | 0 |
|    Fair value of options issued for services         | 1,660,605 |  | 0 |
|    Book value of disposed assets                     | 54,309 |  |  |
| Changes in Operating Assets & Liabilities:                 |  |  |  |
|    Accounts receivable                               | 49,414 |  | 0 |
|    Prepaid expenses                                  | (13,985) |  | 3,307 |
|    Accounts payable                                  | 275,862 |  | 304,746 |
|    Accrued expenses                                  | 267,424 |  | 217,082 |
|    Unearned revenue & customer deposits          | 177,638 |  | (47,635) |
|                                                           |  |  |  |
|   Net cash used by operating activities                   | (1,389,343) |  | (1,306,366) |
|                                                           |  |  |  |
|                                                           |  |  |  |
| *Cash Flows from Investing Activities:*                        |  |  |  |
|   Purchase of Equipment                                   | (37,547) |  | (23,174) |
|   Advances to affiliates and other                        | (105,365) |  | (100,500) |
|                                                           |  |  |  |
|   Net cash used by investing activities                   | (142,912) |  | (123,674) |
|                                                           |  |  |  |
|                                                           |  |  |  |
| *Cash Flows from Financing Activities:*                        |  |  |  |
|   Proceeds from issuance of common stock                  | 0 |  | 902,000 |
|   Payment of capitalized leases                           | (3,619) |  | 16,222 |
|   Loan Proceeds                                           | 687,393 |  | 511,818 |
|   Payment of  debt                                   | (256,027) |  | 0 |
|                                                           |  |  |  |
|   Net cash used by financing activities                   | 427,747 |  | 1,430,040 |
|                                                           |  |  |  |
|                                                           |  |  |  |
| Net Change In Cash                                             | (1,104,508) |  | 0 |
| Cash-Beginning                                                 | 1,111,218 |  | 0 |
|                                                           |  |  |  |
| Cash-Ending                                                    | $6,710 |  | $0 |
|                                                           |  |  |  |
| See notes to unaudited interim financial statements.           |  |  |  |
|                                                           |  |  |  |
| Supplemental disclosure of non-cash transactions:              |  |  |  |
| Value of common stock issued to settle accrued expenses        | 48,961 |  | 313,800 |
| Conversion of accrued expense to 10% debenture                 | 101,250 |  |  |
| Fair Value Shares issued to acquire assets of Cybermedx        | 900,000 |  |  |
| Note issued to relieve restrictive loan covenants              | 450,000 |  |  |

----

**WiFiMed Holdings Company, Inc.**** Notes to Consolidated Financial Statements**** September 30, 2008**** (unaudited)**

**1. Description of Business and Summary of Significant Accounting Policies**

**General**

These financial statements should be read in conjunction with WiFiMed Holdings Company, Inc.'s ("WiFiMed" or the "Company") Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission ("SEC"), on April 16, 2008, and the accompanying financial statements and related notes thereto. The accounting policies used in preparing these financial statements are the same as those described in the Company's Form 10-K for the year ended December 31, 2007.

**Business**

WiFiMed Holdings Company, Inc. (the "Company"), through its wholly-owned subsidiaries as of June 30, 2008, WiFiMed, Inc, EncounterPRO Healthcare Resources, Inc. ("EncounterPRO") and CyberMedx Medical Systems, Inc.("CyberMedx"), develops and sells electronic health record software, as well as associated services and computer hardware, to medical practices. Effective October 1, 2007, the Company acquired substantially all of the assets of JMJ Technologies, Inc., which assets were acquired by the new subsidiary formed for that purpose, EncounterPRO. Effective February 29, 2008, the newly-formed, wholly-owned subsidiary Cybermedx Medical Systems, Inc. acquired substantially all of the assets of Cybermedx Medical Systems, LLC ("CMS, LLC"). That acquisition did not reach the financial thresholds necessary to require disclosure of the historical financial statements and *pro-formas*  of CMS, LLC pursuant to Article 8 of Regulation S-X. Accordingly, the financial statements represent the consolidation of the financial statements of the Company's two wholly-owned subsidiaries as of December 31, 2007.

**Interim Financial Statements**

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the general instructions to Form 10-Q. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results could differ from those estimates.

Operating results for the three and nine months ended September 30, 2008 are not necessarily indicative of the results that may be expected for the year ending December 31, 2008 or any future period.

The accompanying unaudited interim financial statements reflect all adjustments of a normal and recurring nature which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows of the Company for the interim periods presented.

**Principles of Consolidation**

The accompanying consolidated financial statements include the accounts of WiFiMed Holdings Company, Inc. and its wholly owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated in consolidation.  Management makes estimates and assumptions that affect the amounts reported in the financial statements and footnotes. Actual results could differ from those estimates.

**Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Reclassifications**

Certain reclassifications have been made to the December 31, 2007 financial statements to conform with the September 30, 2008 presentation. 

**2. Stock-based employee compensation**

WiFiMed has a stock option plan under which employees, consultants, and other advisors may be issued options to purchase the common stock of the Company.  The plan is administered by the Board of Directors or a committee thereof.

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions used for options granted during the nine months ended September 30, 2008: dividend yield of 0%; expected volatility of 210%; risk-free interest rate of 4.4% and an expected life of 5-10 years. As of September 30 2008 there was $3,274,000 of total unrecognized compensation cost of non-vested share-based compensation arrangements related to stock options granted.

The following table summarizes stock option activity for the nine months ended September 30, 2008:
|                                     |   |      |   |                       |   | ** **
**Weighted            average            exercise price** |   | ** **
**Weighted            average            remaining            contractual            term            (years)** |   | ** **
**Aggregate            intrinsic            value*** |   |
|------------------------------------------|--------|-----------|--------|-----------------------|--------|----------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------|--------|
|                                     |   |      |   |                       |   |
|                                     |   |      |   | ** **
**Shares** |   |
|                                     |   |      |   |                       |   |                                                                      |   |                                                                                                                           |   |                                                                 |   |
| Options outstanding at December 31, 2007 |   | 2,038,711 |   | $0.42                 |   | 8.7                                                                  |   | $1,288,512                                                                                                                |   |
| Granted                                  |   |      |   | 5,998,000             |   | $0.69                                                                |   |                                                                                                                           |   |                                                                 |   |
| Exercised                                |   |      |   | (489,610)             |   | $0.10                                                                |   |                                                                                                                           |   |                                                                 |   |
| Lapsed                                   |   |      |   | 0                     |   | 0                                                                    |   |                                                                                                                           |   |                                                                 |   |
|                                     |   |      |   |                       |   |                                                                      |   |                                                                                                                           |   |                                                                 |   |
| Options outstanding at Sept 30, 2008     |   | 7,547,101 |   | $0.65                 |   | 9.2                                                                  |   | $0                                                                                                                        |   |
|                                     |   |           |   |                       |   |                                                                      |   |                                                                                                                           |   |
| Options exercisable at Sept 30, 2008     |   | 3,945,340 |   | $0.63                 |   | 9.1                                                                  |   | $0                                                                                                                        |   |

*Amount by which the fair value of the stock at the balance sheet date exceeds the exercise price.

The Company also grants stock to employees as a form of compensation. It accounts for such issuances under SFAS 123R. During the first nine months of 2008 we issued 4,000,000 shares, restricted for 3 years, with an aggregate fair value of approximately $3.6 million. Approximately $900,000 of compensation has been recognized through September 30, 2008 while $2,700,000 remains unrecognized.

**3. Net earnings per common share**

Net loss per share is computed in accordance with SFAS No. 128, "Earnings Per Share." We compute basic earnings per share by dividing net income or loss by the weighted average number of common shares outstanding for each period. Diluted net earnings per share is based upon the addition of the effect of common stock equivalents (stock options and warrants) to the denominator of the basic net loss per share calculation using the treasury stock method, if their effect is dilutive. Basic earnings (loss) per share for the three months ended September 30, 2008 and 2007, respectively are $0.03 and $(0.02), respectively, based upon 42,425,429 weighted average shares outstanding in 2008 and 24,941,383 weighted average shares outstanding in 2007. Basic earnings (loss) per share for the nine months ended September 30, 2008 and 2007, respectively are $0.27 and $(0.09), respectively, based upon 40,609,044 weighted average shares outstanding in 2008 and 22,836,886 weighted average shares outstanding in 2007. Fully diluted earning (loss) per share for the three and nine-months ended September 30, 2008 was $.04 and $.22 based upon 62,538,045 and 58,942,369, respectively, weighted average fully diluted shares outstanding. For the three and nine-months ended September 30, 2007, diluted earnings per share is the same as basic earnings per share since the effect on earnings of the conversion of our convertible debt, stock options and warrants would have an anti-dilutive effect on earnings per share.

**4.  Mergers and Acquisitions**

*Acquisition of the Assets of CyberMedx Medical Systems, LLC*--On February 29, 2008, the Company acquired substantially all of the assets of CyberMedx Medical Systems, LLC ("CyberMedx") through its wholly-owned subsidiary CyberMedx Medical Systems, Inc. ("CMS, Inc.") pursuant to the Asset Purchase Agreement, dated February 20, 2008 as disclosed in the Company's Current Report on Form 8-K, filed with the SEC on March 6, 2008. The purchased assets included certain intellectual property rights and contracts; CMS, Inc. assumed only certain liabilities in connection with contracts due to be performed after closing, in addition to compensation to Mr. Ronald Barnett and the business agents (as further described below). As consideration for entering into the Asset Purchase Agreement and consummating the transactions contemplated therein, the Company issued 900,000 restricted shares of common stock, par value $.0001 per share (the "Acquisition Shares") to unit holders of CyberMedx, and may issue up to an additional 900,000 as a post-closing adjustment as calculated in Section 3.5 of the Asset Purchase Agreement in the event the weighted average sales price (weighted for volume) of the Company's common stock is below $1.00 per share on the OTCBB for the thirty consecutive business days preceding the 180th day following the Closing Date.

In connection with the Asset Purchase Agreement, Mr. Barnett entered into an employment agreement, effective as of March 1, 2008, whereby CMS, Inc. employed Barnett as its President and Acting Treasurer for a term of three (3) years (the "Employment Agreement"). The consideration for the Employment Agreement consisted of salary, fixed bonuses, stock options, "earn out" cash bonuses of up to $1.35 million over three years, and common stock subject to partial or full forfeiture, depending upon the financial performance of CMS, Inc. The annual base salary for the first year is $120,000 and is $140,000 for the second year, with salary for the third year dependent upon the financial performance of CMS, Inc. Barnett received a "sign on" bonus of $32,000, payable in semi-monthly installments over the course of the first year of employment, as well as a first annual bonus of $48,000 and a second annual bonus of $56,000, with bonuses for the third year dependent on the performance of CMS, Inc., subject to a cap of 40% of Employee's salary at such time. The Company awarded Barnett a total of one million stock options of the Company. In addition, Barnett was awarded a total of 3.6 million shares of Common Stock upon the commencement of his employment, which shares are subject to forfeiture following each of the three years of employment, depending upon the extent to which CMS, Inc. has met certain financial and product development goals, as further described therein. The same goals will be used to determine the "earn out" cash bonuses that Barnett may earn, up to a maximum of $1.35 million. The parties agreed to a Product Development Bonus, based on certain product development criteria to be negotiated by July 1, 2008, which if met, would entitle Barnett to a maximum annual amount of $45,000 for each of the three years of the contract term, based on the schedule provided therein.

Stanley Hassan, James H. Roache, and Daniel L. Thomas acted as business agents pursuant to the terms of the Agent Acknowledgement and Agreement (the "Agent Agreements") in connection with the sale of assets to CMS, Inc. and Barnett's employment with CMS, Inc. As consideration for services rendered by such business agents regarding the sale of CMS, LLC assets, the employment of Barnett by CMS, Inc. and for entering into the Agent Agreements, 100,000 shares of Common Stock of the Company, were issued in equal parts to Messrs. Hassan, Roache and Thomas (the "Agent Shares"); 400,000 shares of Common Stock of the Company were also issued in equal parts to the aforementioned business agents, however, these shares remain subject to forfeiture following each of the three years of Barnett's employment, depending upon the extent to which CMS, Inc. has met certain financial and product development goals.  In addition, the Company expects to pay each such business agent 1/27th of the gross cash "earn out" bonuses earned by Barnett; which includes the "Product Development Bonus" and the "Earn-Out Cash Bonus" in Sections 2(e) and 2(f), respectively, of the Employment Agreement.

The following summary, prepared on an unaudited pro forma basis, reflects the condensed consolidated results of operations for the nine months ended September 30, 2007, assuming the acquisition of JMJ Technologies and CyberMedx were completed at the beginning of the period:

|                                          |         | ** **
**Pro Forma              Condensed              Statement of              Operations              Nine Months              Ended              Sept 30,              2007** |       | ** **
**Pro Forma              Condensed              Statement of              Operations              Three Months              Ended              Sept 30,              2007** |
|-----------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                          |         |
|                                          |         |
|                                          |         |
|                                          |         |
|                                          |         |                                                                                                                                                                                       |       |                                                                                                                                                                                        |
| Revenue                                       |         | $1,310,483                                                                                                                                                                            |       | $510,627                                                                                                                                                                               |
| Cost of revenue                               | 138,006      |                                                                                                                                                                                  | 47,281     |
|                                          |              |                                                                                                                                                                                  |            |
| Gross margin                                  |         | $1,172,477                                                                                                                                                                            |       | $463,345                                                                                                                                                                               |
|                                          |         |                                                                                                                                                                                       |       |                                                                                                                                                                                        |
| Costs and expenses:                           |              |                                                                                                                                                                                  |            |
| General & administrative                  | 3,121,788    |                                                                                                                                                                                  | 1,063,893  |
| Research & development                    | 179,559      |                                                                                                                                                                                  | 38,850     |
| Interest, net of interest income              | 178,101      |                                                                                                                                                                                  | 48,566     |
|                                          |              |                                                                                                                                                                                  |            |
| Total costs and expenses                      | 3,479,448    |                                                                                                                                                                                  | 1,151,309  |
|                                          |         |                                                                                                                                                                                       |       |                                                                                                                                                                                        |
| Income taxes                                  |         | 0                                                                                                                                                                                     |       | 0                                                                                                                                                                                      |
|                                          |         |                                                                                                                                                                                       |       |                                                                                                                                                                                        |
| Net loss from continuing operations           | ($2,306,971) |                                                                                                                                                                                  | ($687,963) |
|                                          |              |                                                                                                                                                                                  |            |
|                                          |         |                                                                                                                                                                                       |       |                                                                                                                                                                                        |
| Basic and diluted loss per share              | ($0.07)      |                                                                                                                                                                                  | ($0.02)    |
| Weighted average number of shares outstanding | 31,852,902   |                                                                                                                                                                                  | 33,957,399 |
|                                               |              |                                                                                                                                                                                       |            |                                                                                                                                                                                        |  |

**5.  Income Taxes**

At September 30, 2008 the entire deferred tax asset balance was reserved and no provision for income taxes had been reflected for the three months then ended.

In periodically assessing our ability to realize our deferred tax assets, management considers whether it is more likely than not that some portion or all of our deferred tax assets will be realized. Management analyzes several factors including the amount and timing of the scheduled expiration and reversals of our net operating loss carry forwards (NOLs) and deferred tax items, respectively, as well as potential generation of future taxable income over the periods for which the NOLs are applicable. Certain estimates used in this analysis are based on the current beliefs and expectations of management, as well as assumptions made by, and information currently available to, management. Although we believe the expectations reflected in these estimates are based upon reasonable assumptions, we can give no assurance that actual results will not differ materially from these expectations.

**6.  Litigation**

The Company is subject to a variety of claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims, individually or in aggregate, will not have a material adverse impact on the Company's financial position, its results of operations, or its cash flows, these matters are subject to inherent uncertainties and management's view of these matters may change in the future.

**7.  Going Concern**

The Company's financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of approximately $20.4 million at September 30, 2008 and a working capital deficiency of approximately $3.2 million.

The Company's continued existence is dependent upon its ability to raise capital and/or to successfully market and sell its products.  The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

**8.   Derivatives**

We follow the provisions of SFAS No. 133 "Accounting for Derivative Instruments and Hedging Activities" (SFAS No. 133") along with related interpretations EITF No. 00-19 "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock" ("EITF 00-19") and EITF No. 05-2 "The Meaning of ‘Conventional Convertible Debt Instrument' in Issue No. 00-19" ("EITF 05-2").  SFAS No. 133 requires every derivative instrument (including certain derivative instruments embedded in other contracts) to be recorded in the balance sheet as either an asset or liability measured at its fair value, with changes in the derivative's fair value recognized currently in earnings unless specific hedge accounting criteria are met.  We value these derivative securities under the fair value method at the end of each reporting period (quarter), and their value is marked to market at the end of each reporting period with the gain or loss recognition recorded against earnings.  We continue to revalue these instruments each quarter to reflect their current value in light of the current market price of our common stock.  We utilize the Black-Scholes option-pricing model to determine fair value.  Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument's expected remaining life.  These assumptions require significant management judgment.

Per the guidance of EITF No. 00-19 and EITF No. 05-2, the anti-dilution features of the 2007 and 2008 Debentures did not meet the definition of "standard" anti-dilution features. Therefore, the conversion feature of the 2007 and 2008 Debentures was considered an embedded derivative in accordance with SFAS No. 133. Accordingly, we bifurcated the embedded derivative from the Debentures (host contracts) and recorded the liability at its fair value. The fair value of this derivative liability was determined using the Black-Scholes option pricing model. The key inputs for the valuation analysis at December 31, 2007, were a volatility of 174%, common stock value of $0.84 and a risk free interest rate of 4.4%.    

The warrants issued with the 2007 and 2008 Debentures were also classified as a derivative liability. The Registration Rights Agreements, which was initially executed in connection to the issuance of the 2007 Debentures, subjected the Company to cash penalties in the event the registration statement was not effective by a certain date, or for failure to maintain the effectiveness of the registration statement for a specified period of time. The shares issuable upon conversion could be net-cash settled under circumstances beyond traditional liquidation provisions scope exceptions. That Registration Rights Agreement was effectively suspended by the parties, provided that the Company continues to observe its reporting responsibilities for purposes of permitting trading transactions in accordance with SEC Rule 144. The Company may be obligated to pay cash to the holder as "compensation for Buy-In on a failure to timely deliver certificates upon exercise."

The fair value of the derivative liabilities associated with these securities was calculated using the Black-Scholes option-pricing model. Key inputs for the valuation analysis at September 3 0, 2008, were a volatility of 238%, common stock value of $0.05 and a risk free interest rate of 4.4%. The following table summarizes our 2008 derivative activity:
|                                                             |         |         | Embedded            conversion            feature | Warrants |
|------------------------------------------------------------------|--------------|--------------|---------------------------------------------------|----------|
|                                                             |         |         |
|                                                             |         |         |
|                                                             |         |         |
|                                                             |              |              |
| Fair Value at December 31, 2007                                  | $10,127,860  | $10,546,833  |
| Initial fair value of instruments associated with 10% debentures | 394,211      | 342,039      |
| Initial fair value of instruments associated with 5% debentures  | 180,000      |              |
|                                                             |              |              |
| Fair value adjustment at September 30                            | (10,177,034) | (10,154,792) |
|                                                             |              |              |
| Fair Value at September 30, 2008                                 | $525,037     | $734,080     |

**9.  New Debt Financing**

**10% Senior Convertible Debentures**

On May 13, 2008, the Company entered into a Securities Purchase Agreement (the "May Securities Purchase Agreement") with six (6) investors, which include three institutional investors (the "Institutional Holders", collectively with the remaining three accredited investors, the "Purchasers"), as described in the Form 8-K filed on May 15, 2008.

The Company issued 10% Senior Convertible Debentures (the "May Debentures") in the aggregate principal amount of $901,250, of which $601,250 in principal amount of May Debentures were issued to the Institutional Holders and $300,000 in principal amount of May Debentures were issued to three other accredited investors which May Debentures, together with accrued but unpaid interest and any other amounts due thereon, are due and payable on November 13, 2008 (the "Maturity Date"). The Company received subscriptions in the gross amount of $500,000 from the Institutional Holders, however their Debentures included an additional 5% of accrued but unpaid liquidated damages due under the Existing Debentures (as defined below), which amount was added to the subscription amount on a dollar for dollar basis to arrive at the principal amount of such Debentures.

The May Debentures bear interest at the rate of 10% per annum, payable quarterly, in cash. All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 18% per annum or the maximum rate permitted by law. If the Company fails to pay all outstanding principal and interest on the May Debentures by the Maturity Date, the Purchasers shall have the right to convert any outstanding principal or interest in whole or in part, into shares of the Company's common stock at the lesser of (i) $.20 per share or (ii) 85% of the average volume weighted average price for the five trading days immediately prior to conversion, subject to adjustment for certain issuances, stock dividends, stock splits, fundamental transactions or other similar dilutive events.

The Company shall be required to redeem all of the then outstanding principal amount of these May Debentures in the event of a subsequent financing with proceeds of at least $3,000,000 (defined as an Automatic Redemption in the May Debenture). It should be noted that with respect to non-Institutional Holders, they entered into a Subordination Agreement, filed as Exhibit 10.7 to the Form 8-K filed on May 15, 2008, subordinating their right to receive principal and interest upon the Maturity Date to that of the $2,250,000 in principal amount of Original Issue Discount, 5% Senior Convertible Debentures, due May 30, 2010 (the "Existing Debentures"), issued to the Institutional Holders on November 30, 2007; provided however, that such non-Institutional Holders can (i) convert their May Debentures to common stock; and (ii) be repaid in cash pursuant to an Automatic Redemption. These May Debentures are senior to all current and future indebtedness of the Company during the term of the Debentures with the exception of the $250,000 Note to the Bank of North Georgia and the Existing Debentures.

 **Previous Debt Financing: 5% Convertible Debentures**

As previously described in the Company's 10-K filed on April 16, 2008 and on Form 8-K filed on December 6, 2007, the Company entered into and consummated a Securities Purchase Agreement as of November 30, 2007, with the following three institutional investors: Enable Growth Partners LP, Pierce Diversified Strategy Master Fund LLC, and Enable Opportunity Partners LP (the "November Financing").  The aggregate purchase price was $2,025,000, and the investment consisted of Senior Convertible Debentures (the "November Debentures" or "Existing Debentures") in the aggregate principal amount of $2,250,000 which, together with accrued but unpaid interest and any other amounts due thereon, are due and payable on May 31, 2010, or earlier upon acceleration following an Event of Default, as defined in the November Debentures. The November Debentures bear interest at a nominal rate of 5% per annum, payable quarterly, in cash, or additional shares of our common stock in the event certain conditions exist, as described in the November Financing documents.  All overdue accrued and unpaid interest shall entail a late fee equal to the lesser of 12% per annum or the maximum rate permitted by law.

In connection with an concurrently with the consummation of the May Securities Agreement and the issuance of the May Debentures, the Company issued an additional $450,000 in November Debentures to the Institutional Investors to secure those investors' consent to the consummation of the May Securities Purchase Agreement, as described more fully in the Form 8-K and accompanying exhibits filed with the Commision on May 15, 2008.

The principal amount of the November Debentures and accrued interest thereon are convertible into shares of our common stock at the election of the Purchasers at an initial exercise price of $.20 per share, subject to adjustment for certain issuances, transactions or events that would result in dilution to the holders. 

The November Debentures are senior to all current and future indebtedness of the Company during the term of the Debentures with the exception of the $250,000 Note to the Bank of North Georgia, and to the extent permitted under that certain Subordination Agreement, filed as Exhibit 10.5 to the Form 8-K filed in connection with the November Financing on December 6, 2008.  The November Debentures also contain a mandatory prepayment provision, beginning on the eighth month anniversary of the Closing Date, and continuing on the same day of each successive month thereafter for 22 months, the Company must repay 1/22nd of the original principal plus accrued interest on the November Debentures either in cash or common stock, at the Company's option.  The November Financing further provides to the Purchasers warrants to purchase an aggregate of 11,250,000 shares of the Company's common stock at an exercise price of $.50 per share, subject to adjustment, including full-ratchet anti-dilution protection, and are exercisable for a period of five years (the "November Warrants").  The November Warrants may also be exercised on a "cashless" basis if at any time after the earlier of (i) the one year anniversary of the date of the Purchase Agreement and (ii) the completion of the then-applicable holding period required by Rule 144, or any successor provision then in effect, there is no effective Registration Statement registering, or no current prospectus available for, the resale of the shares underlying the November Warrants.  The option of each Purchaser to convert the November Debentures, or exercise the November Warrants, is subject to the restriction that such conversion or exercise, does not result in the Purchaser beneficially owning at any one time more that 4.99% of our outstanding shares of common stock. 

Collectively, the 2008 convertible debt securities were issued with a non-detachable conversion feature and 4,000,000 detachable warrants. The values ascribed to the note, the conversion feature of the note, other potential embedded derivative features, and detachable warrants follow the guidance of EITF Issue No. 00-19,*  Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock*; SFAS No. 150,*  Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity* ; and EITF Issue No. 00-27, *Application of Issue No. 98-5 to Certain Convertible Instruments*. In accordance with EITF Issue No. 00-19, a transaction which includes a potential for net-cash settlement, including liquidated damages, requires that derivative financial instruments, including warrants and the embedded conversion feature, be bifurcated, and initially recorded at fair value as an asset or liability and subsequent changes in fair value be reflected in the statement of operations.

The terms of the convertible debentures include a conversion price reset feature which provides for a reduction in conversion price of the debentures into shares of the Company's common stock at a rate equal to the terms of any future offering. The monthly redemption provision also provides that if payment is to be made in shares then such share amount is to be determined by an adjustment to the conversion price determined by discounting by 10% the volume weighted average price of the common stock for a 10 day trading period immediately before the redemption date. Because the conversion option is indexed to our own stock and a separate instrument with the same terms would be classified in stockholders' equity in the statement of financial position, the written option was not considered to be a derivative instrument for the issuer under SFAS 133 paragraph 11(a). However, under EITF 00-19 we have determined that the current conversion rates are not fixed and determinate and will change in circumstances outside management's control and, accordingly, the conversion feature was separated from the host contract.

These debentures were considered to have an embedded beneficial conversion feature because the effective conversion price was less than the quoted market price at the time of the issuance. The Company allocated the proceeds of the debt between the warrants and the debt based on relative fair values. The beneficial conversion feature of $394,211 and $180,000 for the 10% and 5% debentures, respectively, was recorded separately based on the intrinsic value method per EITF 98-5. The intrinsic value of the beneficial conversion feature exceeded the proceeds allocable to the convertible debt; therefore, the amount of the discount and derivative liability initially assigned to the beneficial conversion feature was limited to the amount of the proceeds allocable to the convertible debt.

The terms of the warrants also include a reset conversion feature which provides for a reduction in conversion price of the debentures into shares of the Company's common stock at a rate equal to the terms of any future offering. The monthly redemption provision also provides that if payment is to be made in shares then such share amount is to be determined by an adjustment to the conversion price determined by discounting by 10% the volume weighted average price of the common stock for a 10 day trading period immediately before the redemption date. Because the conversion option is indexed to our own stock and a separate instrument with the same terms would be classified in stockholders' equity in the statement of financial position, the written option was not considered to be a derivative instrument for the issuer under SFAS 133 paragraph 11(a). However, under EITF 00-19 we have determined that the current conversion rate is not fixed and determinate and will change in circumstances outside management's control and, accordingly, derivative treatment applies. The fair value ascribed to the warrants exceeded the proceeds allocable; therefore, the amount of the discount and derivative liability initially assigned to the warrants was limited to the amount of the proceeds allocable or $342,039.

We utilize the Black-Scholes option-pricing model to determine fair value of the note, conversion feature and warrants.  Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument's expected remaining life. Assumptions used in the initial valuation were dividend yield of 0%; expected volatility of 210%; risk-free interest rate of 4.4% and an expected life ranging between 4 months to 5 years.

**Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations****.**

***Statement Regarding Forward-Looking Disclosure***

*Certain statements contained in this report, including, without limitation, statements containing the words, "likely," "forecast," "project," "believe," "anticipate," "expect," "plan," "may," "should," and the negative or other variations of these words and other words of similar meaning, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revision of the forward-looking statements contained or incorporated by reference herein to reflect future events or developments. In addition to the forward-looking statements contained in this report, the following forward-looking factors could cause our future results to differ materially from our forward-looking statements: competition, capital resources, credit resources, funding, government compliance and market acceptance of our products and services. We make these statements under the protection afforded by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.*

In this report, "we," "us," "our," the "Company," and "WiFiMed" refer to WiFiMed Holdings Company, Inc. and its wholly-owned subsidiaries as of September 30, 2008, unless the context indicates otherwise. Our trademarks include EncounterPRO®, Tablet MD®, WaveLynxTM, C[caduceus]METM, CareSymphonyTM and Magic TriangleTM. Other trademarks, service marks and trade names referred to in this report, or documents incorporated or incorporated by reference herein or therein, are the property of their respective owners.

**The following discussion and analysis provides information, which WiFiMed management believes is relevant to an assessment and understanding of WiFiMed's results of operations and financial condition and should be read in conjunction with the consolidated financial statements and notes thereto presented elsewhere in this report.**

**Overview**

WiFiMed began operations as WiFiMed, LLC, a Georgia limited liability company, in November 2002 and reorganized as WiFiMed, Inc., a Delaware corporation on or about March 21, 2006.  In March 2007, WiFiMed merged with and into a wholly-owned subsidiary of Bellacasa Productions, Inc. (which was subsequently renamed WiFiMed Holdings Company, Inc.) with WiFiMed, Inc remaining as the surviving entity.  For accounting purposes the consummation of these actions resulted in a reverse merger with WiFiMed, Inc. as the accounting acquirer and surviving operating entity.  Thus, the historical financial statements of the Company prior to the effective date of the Bellacasa merger were restated to be those of WiFiMed, Inc.

In October 2007, the Company acquired substantially all of the assets of JMJ Technologies, Inc., which included JMJ's flagship product—the EncounterPRO EHR, a nationally-acclaimed electronic health record or "EHR" with more than 300 medical practices charting medical records for an estimated three million patients. In addition, 26 employees of JMJ had been employed by the Company, and JMJ's management supplanted the previous management of the Company, with the exception of the board of directors which remained largely intact.

On February 29, 2008, the Company's wholly owned subsidiary, CyberMedx Medical Systems, Inc. ("CMS Inc.") purchased the assets and know-how of CyberMedx Medical Systems, LLC ("CMS, LLC") pursuant to the Asset Purchase Agreement, dated February 20, 2008, in exchange for consideration of 900,000 shares of the Company's common stock to the unit holders of the CMS, LLC (with another 100,000 shares of common stock to be escrowed for one year for the benefit of the unitholders and to provide a ready source of recovery for any claims by the Company for indemnity), and 100,000 shares of common stock to certain business agents in connection with the arrangement of the transaction, in addition to up to an additional 900,000 shares of the Company's common stock as a post-closing adjustment, among other consideration more fully described therein. In connection with the Asset Purchase Agreement, CMS, Inc. entered into an employment agreement with Ronald R. Barnett (the "Employment Agreement"), as described more fully in the Company's Form 8-K, filed with the Commission on March 6, 2008.

At September 30, 2008, WiFiMed had an accumulated deficit of approximately $20.5 million.

WiFiMed's offices are located at 2000 RiverEdge Parkway, Suite GL 100A, Atlanta, GA 30328, its phone number is (770) 919-7220 and its website is www.wifi-med.com.

**Critical Accounting Policies**

**Revenue recognition**

The Company's revenue consists of fees derived from (1) the licensing of software to end user customers; (2) related services, including installation, training, implementation, and software support; and (3) the resale of certain computer equipment.

The Company recognizes software license revenue under Statement of Position No 97-2 "Software Revenue Recognition" as amended by Statement of Position No. 98-9, "Software Revenue Recognition With Respect to Certain Transactions," Emerging Issues Task Force 00-21, "Revenue Arrangements with Multiple Deliverables," and related interpretations.

Sales of licensed software are recognized as revenue upon delivery and installation of the software at the customer site.  Sometimes our agreements with customers include acceptance provisions, in which case revenue is not recognized prior to customer acceptance.  Regardless of the form of sale, no revenue is recognized without persuasive evidence of an arrangement existing.  Persuasive evidence is determined to be a signed purchase order received from the customer or an equivalent form for those customers lacking a formalized purchase order system.  In the case where customer acceptance is required, persuasive evidence includes this customer acceptance documentation.  In the case of software license sales, a software license agreement signed by both parties is often required in addition to a purchase order or equivalent.  Additionally, revenue is only recognized when a selling price is fixed or determinable and collectability of the receivable is deemed to be probable.

Service revenues such as training, installation and implementation are recognized when the service is complete and acknowledged by the customer.  Fees charged to customers for post-contract customer support are recognized ratably over the term of the contract.  Costs related to maintenance obligations are expensed as incurred. Revenue allocated to maintenance is recognized ratably over the maintenance term and revenue allocated to training and other service elements is recognized as the services are performed.

Sales which constitute a multiple-element arrangement are accounted for by determining if the elements can be accounted for as separate accounting units, and if so, by applying values to those units for which there is vendor specific objective evidence of their fair value.  We use the residual method to apply any remaining balance to the remaining elements of the arrangement.  More specifically, this methodology applies when there is embedded maintenance (post-contract customer support) involved in the sale of a software license, or when the sale of a software license is made in conjunction with required installation services.  In the latter case, the recognition of the software license is deferred until installation is completed.  Fees relating to the delivery of equipment are also incurred and deferred until recognition of the software license is appropriate, and shown on the balance sheet as deferred cost of goods sold.

The Company's revenues generated through hosting solutions are recognized using the proportional performance method.  Revenues are recognized in the month services are rendered and earned under service agreements with clients where service fees are fixed or determinable.  Accounts receivable are recorded when the Company invoices its customer for goods and/or services rendered, pursuant to contractual terms.  Purchased inventory is reduced at the time that goods are shipped to the customer.

**Software Development Expenditures**

The Company accounts for its software development costs that will be sold, leased, or otherwise marketed in accordance with Statement of Financial Accounting Standards Board ("FASB") 86 "Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed."  Accordingly, software development costs are capitalized once technological feasibility has been established and continues until the product is available for general market release.  These capitalized costs are subject to an ongoing assessment of recoverability based on anticipated future revenues and changes in hardware and software technologies.  During the nine month periods ended September 30, 2008 and September 30, 2007, the Company expensed software development costs as incurred because the net realizable value was not assured.  These costs totaled $56,621and $179,559 for the nine month periods ended September 30, 2008 and September 30, 2007, respectively. 

**Recent Accounting Policies**

In February 2007, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115." SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value at specified election dates. This Statement applies to all entities, including not-for-profit organizations. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. As such, the Company adopted these provisions at the beginning of the fiscal year ending December 31, 2008.  Adoption of SFAS 159 did not have a significant effect on the Company's financial statements.

In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157, "Fair Value Measurements." SFAS 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. As such, the Company adopted these provisions at the beginning of the fiscal year ending December 31, 2008.  Adoption of SFAS 157 did not have a significant effect on the Company's financial statements.

  In December 2007, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 141(R), "Business Combinations." SFAS 141(R) establishes principles and requirements for how the acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase, and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. SFAS 141(R) is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. As such, the Company is required to adopt these provisions at the beginning of the fiscal year ending December 31, 2009. The Company does not expect adoption of SFAS 141(R) to have a material effect on its financial statements.

In December 2007, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 160, "Non-controlling Interests in Consolidated Financial Statements, an amendment of ARB No. 51." SFAS 160 establishes accounting and reporting standards for the non-controlling interest in a subsidiary and for the deconsolidation of a subsidiary. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. As such, the Company is required to adopt these provisions at the beginning of the fiscal year ending December 31, 2009. The Company does not expect SFAS 160 to have a material effect on its financial statements.

**Quarterly Financial Information**

**Material Changes in Results of Operations For the Nine Month Period Ended September 30, 2008 As Compared to the Nine Month Period Ended September 30, 2007.**

**Revenues** – Revenues for the nine months ended September 30, 2008 were $1,326,618 compared to $0 for the nine months ended September 30, 2007. The increase in revenue is primarily the result of the acquisition of the assets of JMJ Technologies, as well as the merger with WiFiMed, Inc.

**Costs and Expenses** - Total operating expenses for the nine months ended September 30, 2008 were $9,589,397, compared to $2,010,351 in the nine months ended September 30, 2007.

Selling, general and administrative expenses in the   months ending September 30, 2008 were $8,358,288, which consisted primarily of payroll and related employee expenses of $4,590,560 (this includes $2,781,034 of amortized deferred equity based compensation under SFAS 123R); professional fees of $308,514 for legal fees and $231,545 for accounting and audit fees; and $2,514,617 for consulting (of which $2,398,105 was non-cash paid in the form of stock and warrants at fair value).  Net Interest expense for the period was $2,049,149. Interest expense included amortization of $1,396,875 in debt discounts arising from the impact of EITF 98-5 and the resultant bifurcation and recognition of the fair value of embedded the beneficial conversion features and detachable warrants on the 10% and 5% debentures consummated in May, 2008. Interest expense also includes one-time charges for registration rights penalties and the costs associated with obtaining release on restrictive covenants totaling $552,851.

*Derivatives*:

The conversion feature and detachable warrants associated with debt instruments entered into in 2007 and 2008 contain conversion features and warrant conversion formulas that contain elements precluding equity treatment under FAS 333 and EITF 00-19. SFAS No. 133 requires every derivative instrument (including certain derivative instruments embedded in other contracts) to be recorded in the balance sheet as either an asset or liability measured at its fair value, with changes in the derivative's fair value recognized currently in earnings unless specific hedge accounting criteria are met.  We value these derivative securities under the fair value method at the end of each reporting period (quarter), and their value is marked to market at the end of each reporting period with the gain or loss recognition recorded against earnings.  We continue to revalue these instruments each quarter to reflect their current value in light of the current market price of our common stock.  We utilize the Black-Scholes option-pricing model to determine fair value. The fair value of the derivative liabilities associated with these securities was calculated using the Black-Scholes option-pricing model. Key inputs for the valuation analysis at September 30, 2008 were a volatility of 238%, common stock value of $.05 and a risk free interest rate of 4.4%. The fair value at September 30, 2008 was determined to be $1,259,117. The valuation gain of $20,331,826 is the combined result of revaluation of derivatives carried at $20,674,693 at December 31, 2007 and the addition of  the initial valuation of $736,250 and $180,000 in derivatives  associated with the 2008 5% and 10% financing. The principal driver in the reduction of fair value was the decline in our stock price from $.84 to $.05.

Selling, general and administrative expenses in the nine months ending September 30, 2007 were $1,802,690 which consisted primarily of payroll and related employee expenses of $927,460; professional fees of $268,662 for legal and accounting services; $159,340 for commissions; and $52,664 for travel, meals and entertainment.  Other expenses for the period were research and development, $179,559; and depreciation, $14,955.  Net Interest expense for the period was $21,336.

**Net Income** - Net income, before taxes, for the nine months ended September 30, 2008 was $10,916,016.  Net loss, before taxes, for the nine months ended September 30, 2007 was $(2,010,351).  The net change of approximately $13 million resulted from an additional $7.1 million in non-cash financing charges, amortization of debt discount, stock issued for services and amortization of equity-based compensation in 2008, offset by a $20.3 million non-cash decrease (gain) in the value of derivatives.

**Net Earnings per Share** - Basic earnings (loss) per share for the three months ended September 30, 2008 and 2007, respectively are $.03 and $(.02), respectively, based upon 42,405,429 weighted average shares outstanding in 2008 and 24,941,383 weighted average shares outstanding in 2007. Basic earnings (loss) per share for the nine months ended September 30, 2008 and 2007, respectively are $.27 and $(.09), respectively, based upon 40,609,044 weighted average shares outstanding in 2008 and 22,836,886 weighted average shares outstanding in 2007. Fully diluted earning (loss) per share for the three and nine-months ended September 30, 2008 was $.04 and $.22 based upon 62,538,045 and 58,942,369, respectively, weighted average fully diluted shares outstanding. For the three and nine-months ended September 30, 2007, diluted earnings per share is the same as basic earnings per share since the effect on earnings of the conversion of our convertible debt, stock options and warrants would have an anti-dilutive effect on earnings per share.

**Material Changes in Financial Condition, Liquidity and Capital Resources as of September 30, 2008**

**Liquidity and Capital Resources**

As of September 30, 2008, WiFiMed's cash balance was $6,710, as compared to $1,111,218 on December 31, 2007.  The decrease in cash on hand from December 31, 2007 was primarily a result of operating expenses incurred by the Company.  At September 30, 2008, WiFiMed had an accumulated deficit of approximately $20.5 million and working capital deficit of approximately $3.2 million.  As disclosed below, WiFiMed requires additional working capital in order to develop its business operations.

As of September 30, 2008, WiFiMed liabilities (excluding derivatives) totaled approximately $4.5 million, which consisted of accounts payable of $852,408; accrued expenses of $606,444; loans payable of $311,847; deferred and unearned revenue of $941,682, and convertible debt of with a carrying value of $1,741,775, net of discounts, that carry a maturity value of $3,601,250. $901,250 of the notes mature November 13, 2008.

As of December 31, 2007, total liabilities were approximately $2.3 million, excluding derivatives of approximately $20.7 million; accounts payable of $629,174; accrued expenses of $317,447; loans payable of $480,105; capital lease obligations of $18,488; unearned revenues of $764,044 and $74,900 of 5% senior convertible debt.

On May 13, 2008, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with six (6) investors, which include three institutional investors (the "Institutional Holders," collectively with the remaining three accredited investors, the "Purchasers") providing for the issuance of 10% Senior Convertible Debentures and Warrants in the aggregate principal amount of $901,250 (the "Financing"), as reported in the Company's Current Report on Form 8-K, filed with the SEC on May 15, 2008.  The net proceeds from the Financing was used for working capital purposes, in addition to making payments to the Arkansas investors under the Consent Order, incorporated by reference as Exhibit 10.1 to the 10-Q report filed on May 20, 2008, and making interest payments under those certain Debentures issued as of November 2007. 

Aside from the Financing, WiFiMed intends to meet its cash needs for the next 12 months by the sale of additional securities or borrowings, subject to the terms of the various financing agreements the Company has with its investors.** ** WiFiMed needs to raise approximately $10 million in capital in order to pursue its business plan over the next 12 months, including a proposed acquisition and the required additional financing may not be available on acceptable terms, or at all.  Other than the Company's recent Financing, no binding commitment for an investment in WiFiMed has been made, and a number of factors beyond its control may make any future financings uncertain.  There is no assurance WiFiMed will be able to sell its securities or borrow funds to pursue its business objectives.  WiFiMed will require the infusion of capital to sustain planned growth and failure to raise enough capital to continue operations may hold a significant risk to its shareholders.

**Ability to Continue as a Going Concern and Plan of Operation**

WiFiMed's consolidated financial statements, which are included in this report, have been presented on a going concern basis, which contemplates the realization and the satisfaction of liabilities in the normal course of business.  WiFiMed liquidity has been adversely affected by losses of more than $20 million since its incorporation date, December 2004, which raises substantial doubt about WiFiMed's ability to continue as a going concern without additional capital contributions and/or achieving profitable operations.  WiFiMed's management's plan includes raising additional capital either in the form of common stock or convertible securities and continuing its research and development efforts.  There can be no assurance, however, that WiFiMed will be successful in accomplishing its objectives.

**Capital Expenditures**

During the nine months ended September 30, 2008 and September 30, 2007 WiFiMed purchased $37,548 and $23,174, respectively, of capital equipment, largely computer equipment, software and demonstration units.

**Research and Development**

WiFiMed spent $56,621 on research and development activities for the nine months ended September 30, 2008, as compared with $179,559 for the nine months ended September 30, 2007.  These activities were focused on developing and refining our proprietary technology which needed less work during the current year.

**Item 3.  Quantitative and Qualitative Disclosure About Market Risk.**

The Company, as a smaller reporting company, is not required to provide the information required by this item pursuant to Item 305 of Registration S-K.

**Item 4T.  Controls and Procedures**

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including our principal executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Exchange Act, as of September 30, 2008.  Based on this evaluation, our principal executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that our disclosure and controls are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management, including our chief executive officer and chief financial officer, do not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, will be detected.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls over financial reporting that occurred during the period ended September 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**Item 1.  Legal Proceedings**

On June 12, 2008, Clements Bernard Miller, LLP, the successor law firm to one of WiFiMed, Inc.'s former law firms, filed suit in the State Court of Cobb County, Georgia, against WiFiMed, Inc. seeking payment of allegedly outstanding fees.  The suit was voluntarily dismissed without prejudice on July 14, 2008, and re-filed in substantially the same form in the State Court of Fulton County, Georgia on July 14, 2008.

On November 12, 2008, Charles LaLoggia filed suit in the Superior Court of Fulton County, Georgia, against WiFiMed Holdings Company, Inc. seeking payment of a loan to the Company's predecessor, Bellacasa Productions, Inc. 

Other than as described in this "Legal Proceedings" section and in the Legal Proceedings section of the Form 10-K for the year ended December 31, 2007, no director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to it in reference to pending litigation.
**Item 1A.  Risk Factors**
As a smaller reporting company, the Company is not required to provide the information required by this item.  However, except as set forth below, there are no material changes from risk factors as previously disclosed in the Company's Form 10-K for the year ended December 31, 2007.

As disclosed in the Company's Form 8-K filed on May 15, 2008, the Company entered into a Consent, Waiver and Amendment Agreement on May 13, 2008, pursuant to which the institutional holders of $2,250,000 in principal amount of Original Issue Discount 5% Senior Convertible Debentures due May 30, 2010 (the "Existing Debentures") and warrants agreed to permit the Company to withdraw the registration statement the Company filed to register the shares of common stock underlying the Existing Debentures and Warrants on the condition that Rule 144 will be available for unrestricted re-sales of those securities following the six month holding period.    The Company issued $101,250 in principal amount of 10% Senior Convertible Debenture to the institutional holders on May 13, 2008, in consideration of 5% of accrued but unpaid liquidated damages under the Existing Debentures, in addition to their purchase of $500,000 of such Existing Debentures.  Accordingly, the risk factor "The November 2007 Financing Agreements Require That Our Registration Statement Became Effective Within 90 Days After the Closing Date (120 days in the event of SEC review) which Has Not Happened Forcing Us To Incur Liquidated  Damages" is hereby eliminated.

In addition, although the Company received gross proceeds of $800,000 through June 30, 2008, as disclosed in the above-described Form 8-K, its need for additional funding, as described in the Risk Factors, remains unchanged.

**Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.**

    None.

**Item 3.  Defaults Upon Senior Securities.**

The Company has defaulted on the payment of principal, interest and late fees due under the terms of the May Debentures described in Section 9 of Part I.  The total principal amount of the May Debentures, $800,000 was due in its entirety on November 13, 2008.  The total arrearage (including principal, interest and late fees) due as of November 14, 2008 is approximately $950,000.

In addition, the Company has defaulted on the payment of interest payments, late fees and monthly principal payments on the November Debentures described in Section 9 of Part I.  The total arrearage due as of November 14, 2008 on the November Debentures (including principal, interest and late fees) is approximately $585,000.  As of November 14, 2008, the holders of the November Debentures have not accelerated the debt.

**Item 4.  Submission of Matters to a Vote of Security Holders. **

On September 16, 2008, the annual meeting of the Company's shareholders was held in Atlanta, Georgia.  The purpose of the meeting was:
    - To elect five persons to the board of directors of the Company, each to serve until the next annual meeting of stockholders of the Company or until such person shall resign, be removed or otherwise leave office;
    - To ratify the appointment of Rotenberg & Co., LLP, as independent auditors and accountants for the Company for the fiscal year ending December 31, 2008;
    - To consider and act upon a proposal to amend the Company's articles of incorporation ("Articles of Incorporation") to increase the number of authorized shares of common stock of the Company ("Common Stock") from 75,000,000 shares to 500,000,000 shares of Common Stock;
    - To consider and act upon a proposal to approve the First Amended and Restated WiFiMed Holdings Company, Inc. 2008 Long-Term Incentive Plan;
    - To consider and act upon any other proposal as may properly come before the Annual Meeting or any adjournment thereof.

With respect to the election of directors, each then-current directors was elected to serve another term as director.  The five directors and the votes for and against each were as follows:
| **Director**     | For        | Withheld  | Abstentions | Broker Non-Vote |
|------------------|------------|-----------|-------------|-----------------|
| Marshall Sterman | 29,728,634 | 0         | 10,000      |            |
| Richard Burtt    | 29,728,634 | 0         | 10,000      |            |
| David Hubbard    | 29,728,634 | 0         | 10,000      |            |
| Robert Coffill   | 29,728,634 | 0         | 10,000      |            |
| Gregory Vacca    | 29,728,634 | 3,067,382 | 10,000      |            |

With respect to the other matters voted upon at the annual shareholders' meeting, the ratification of the appointment of Rotenberg & Co., LLP was approved; the increase in the number of authorized shares was approved; and the incentive plan was not adopted.  The votes on those proposals were as follows; no other matters were submitted for a vote.
| **Proposal**                         | For        | Against   | Abstentions | Broker Non-Vote |
|--------------------------------------|------------|-----------|-------------|-----------------|
| Ratify appointment of auditors       | 32,658,622 | 146,521   | 873         |                 |
| Increase number of authorized shares | 29,055,459 | 3,749,684 | 873         |                 |
| Approve Incentive plan               | 19,869,227 | 2,550,037 | 0           |                 |

**Item 5.  Other Information.**

None.

**Item 6.  Exhibits.**
| **Exhibit          No.** |   | **Description**                                                                                                                                                  |   | **Location** |
|--------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|
| 31.1                     |   | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |   | *            |
| 31.2                     |   | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |   | *            |
| 32.1                     |   | Certification of the Chief Executive Officer pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.             |   | *            |
| 32.2                     |   | Certification of the Chief Financial Officer pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002              |   | *            |
| 99.1                     |   |                                                                                                                                                             |   | (5)          |

* Filed herewith.

----

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned as a duly authorized officer of the Registrant.

DATED:  November 14, 2008                                     WiFiMed Holdings Company, Inc.

By: /s/ Gregory D. Vacca                                 Gregory D. Vacca       Chief Executive Officer and       Principal Financial Officer

**WiFiMed Holdings Company, Inc. **

**Quarterly Report on Form 10-Q    Quarter Ended September 30, 2008**

EXHIBIT INDEX
| Exhibit Number | Description                                                                                                                                                      |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|           |                                                                                                                                                             |
| 31.1           | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2           | Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1           | Certification of the Chief Executive Officer pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.             |
| 32.2           | Certification of the Chief Financial Officer pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.             |